Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2022-07-12 Regulatory Filings
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(ABL202 관련 마일스톤 기술료 배분)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the receipt of milestone payments related to a technology transfer agreement (ABL202). Since this is a specific corporate announcement regarding business operations and financial events that does not fit into the other specialized categories like dividends or share repurchases, it is classified as a general regulatory filing.
2022-07-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (under the Financial Investment Services and Capital Markets Act) used to disclose significant changes in share ownership by major shareholders and their special related parties. This document specifically details the shareholding status and changes (disposal of shares) for ABL Bio. This type of filing is classified as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-07-01 Korean
투자판단관련주요경영사항(ABL001 관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding the receipt of a milestone payment (technology fee) from Compass Therapeutics for the drug ABL001. It details the financial impact (USD 6 million) and the nature of the milestone. Since this is a specific corporate event announcement regarding business operations and financial impact that does not fit into categories like dividends, share issues, or management changes, it is classified as a general regulatory filing (RNS).
2022-06-27 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, purpose, and method of the event. Since it is an announcement of an event rather than the presentation slides themselves or a full report, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2022-06-02 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients due to employee departures. This type of filing is a standard regulatory disclosure regarding capital structure and compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for insider trades) or 'Remuneration Information' (which is typically for executive compensation disclosures in proxy statements).
2022-05-31 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, purpose, and method of the event (conference call). Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it falls under the category of a Report Publication Announcement or general regulatory filing regarding an event. Given the specific nature of announcing an IR event, it fits best as a Report Publication Announcement (RPA).
2022-05-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.